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Background: The TNF-like weak inducer of apoptosis (TWEAK) contributes to kidney inflammation producing
secretion by renal cells. The present study examined whether the level of TWEAK is associated with histologic
findings in patients with IgA nephropathy (IgAN).
Methods: The levels of urinary TWEAK (uTWEAK) from 116 IgAN patients, 50 non-IgA kidney disease patients, and
50 healthy individuals were measured by ELISA. Histological findings of renal biopsy specimens of patients with
IgAN were evaluated according to the Oxford classification and histological classification for IgAN in Japan. We
investigated the expression of TWEAK/Fn14 in renal tissues of those patients and assessed the effect of TWEAK in
glomerular mesangial cells and podocytes.
Results: The levels of uTWEAK in the patients with IgAN and other renal diseases were significantly higher than
in the healthy controls (P < 0.001). In the IgAN patients, the levels of uTWEAK correlated significantly with urinary
protein excretion and extracapillary proliferation (r = 0.54, P < 0.001 and r = 0.32, P < 0.001, respectively). In a
comparison of the levels of uTWEAK at diagnosis with that of follow-up, the levels of uTWEAK in patients with
clinical and partial remission decreased significantly. We showed not only increased expression of both TWEAK
and Fn14 in IgAN patients with glomerular crescents but also TWEAK-induced cell motility in podocytes.
Conclusions: The relationship between the levels of uTWEAK and clinicopathological findings observed in this
study suggests that TWEAK/Fn14 system affects crescent formation and proteinuria in patients with IgAN.
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The TNF-like weak inducer of apoptosis (TWEAK,
TNFSF12), a TNF superfamily member, is synthesized as
a type II transmembrane glycoprotein that circulates
in plasma as a soluble form [1]. TWEAK is widely
expressed in many cells and tissues including mono-
cytes/macrophages, the heart, the brain, and kidneys [2].
The binding of TWEAK to its receptor, fibroblast
growth factor-inducible-Fn14 (Fn14) [3,4], regulates
cellular proliferation, differentiation, migration, inflam-
mation, and apoptosis [5]. The plasma levels of soluble
TWEAK have been reported to be associated with the
aggravation of the endothelial function and mortality
risk [6,7]. Recent studies have further indicated that
the levels of urinary TWEAK (uTWEAK) correlated* Correspondence: yasu@juntendo.ac.jp
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unless otherwise stated.positively with lupus nephritis activity [8,9]. These
findings suggest that TWEAK expression may reflect
kidney inflammation and is associated with chronic
kidney disease (CKD).
IgA nephropathy (IgAN) is the most common form of
primary glomerulonephritis worldwide [10] and is one of
the leading causes of end-stage renal disease (ESRD)
[11]. The histologic features of IgAN show an increase
in mesangial proliferation with matrix expansion; other
glomerular lesions may include focal necrosis, segmental
sclerosis, and crescent formations [12]. Podocyte injury
is a common denominator in many forms of human
glomerular diseases [13] and is characteristic of proteinuric
kidney diseases, including IgAN [14]. Notably, podocyte
loss from the glomerular basement membrane (GBM) in
IgAN may cause the progression of proteinuria and glomer-
ulosclerosis [15,16].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cells, glomerular mesangial cells, and podocytes [17,18].
TWEAK induces the expression of inflammatory cyto-
kines, such as monocyte chemoattractant protein-1
(MCP-1), interleukin (IL)-6, RANTES, and CXCL16, and
downregulates the expression of Klotho [19-22]. There-
fore, TWEAK has proinflammatory effects on glomeru-
lar mesangial cells and podocytes [18,23], suggesting the
pathological roles of the TWEAK/Fn14 system in the
pathogenesis of glomerular injury. However, it is un-
known how TWEAK contributes to the pathogenesis of
IgAN. In the present study, we examined whether the
levels of TWEAK are associated with histological
findings and disease activity in patients with IgAN. In
addition, we investigated the expression of TWEAK/
Fn14 in the renal tissues of those patients and assessed
the effect of TWEAK in glomerular mesangial cells and
podocytes.Methods
Patients and controls
This study included patients who had undergone renal
biopsy in the Juntendo University Hospital, Tokyo,
Japan, from January 2005 to March 2011. Although we
recruited 236 patients with biopsy-proven IgAN dur-
ing this period, 96 patients were not included because
urine samples were not obtained or there was poor
conservation of pathologic materials. Of the remaining
140 patients, 15 had insufficient clinical data and thus
were excluded. Nine of the remaining 125 renal biopsy
samples contained less than 8 glomeruli, and thus
were excluded according to the Oxford classification
[24,25]. In the end, 116 patients with IgAN were in-
cluded in this study.
We enrolled 50 patients with non-IgAN kidney dis-
eases, including 12 patients with minimal change disease
(MCD), 12 patients with membranous nephropathy
(MN), 18 patients with lupus nephritis (LN), and 8 pa-
tients with focal segmental glomerulosclerosis (FSGS) as
disease controls. We also recruited 50 healthy subjects
to serve as healthy controls.
Of the 116 patients with IgAN, 37 patients had
follow-up data. They received steroid therapy (n = 8)
or both steroid therapy and tonsillectomy (n = 29).
The steroid therapy regimen consists of 0.5 g/day of
methylprednisolone for 3 days, three times every
2 months, and patients were given oral prednisolone
(0.5 mg/kg body weight) on alternate days for
6 months. The evaluation of therapeutic response of
the IgAN patients was defined as follows [26]: clinical re-
mission (CR, proteinuria <0.3 g/gCr with urinary sediment
RBC <5 /HPF), partial remission (PR, proteinuria <0.3 g/
gCr or urinary sediment RBC <5 /HPF).This study was conducted according to the Declar-
ation of Helsinki and was approved by Institutional
Review Board of Juntendo University Hospital. In-
formed consent was obtained from all patients and
healthy subjects.Sample collection
At the time of renal biopsy, all patients provided blood
and freshly voided urine samples. The sera and super-
natant from urine were separated by centrifugation, and
were then stored in aliquots at −80°C prior to measure-
ment. Urine samples from the 37 patients with follow-
up were also collected and stored.Measurement of human serum and urinary TWEAK
The levels of serum TWEAK (sTWEAK) and uTWEAK
were determined in duplicate with commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN), following the manu-
facturer’s protocol. TWEAK assays were performed
blindly, without knowledge of the patients’ disease status
or activity.Measurement of other markers
Serum and urine measures from patients were deter-
mined in the clinical laboratory center in the Juntendo
University Hospital. Levels of urinary protein excre-
tion and uTWEAK were individually normalized to
urinary creatinine levels. The estimated glomerular fil-
tration rate (eGFR) was calculated using the Japanese
eGFR equation [27].Pathologic analysis
All renal biopsy specimens were evaluated with im-
munofluorescence, light-, and electron microscopy. For
light microscopy, paraffin sections were stained with
hematoxylin-eosin (HE), periodic acid-Schiff (PAS), and
periodic acid methenamine silver-Masson trichrome
(PAM-MT). The Oxford classification was used to evalu-
ate histologic findings of renal biopsy specimens of IgAN
patients [24,25]. We also evaluated renal biopsy sections
using the histological classification for IgAN in Japan
[28], of which the prognosis classification is as follows:
global sclerosis, segmental sclerosis, or cellular/fibrocel-
lular/fibrous crescent were observed in <25% (Grade I),
25–49% (Grade II), 50–74% (Grade III) and ≥75%
(Grade IV) of all glomeruli. The percentage of glomeruli
with each glomerular lesion was analyzed. The histo-
logic findings of each slide were evaluated by two ne-
phrologists who did not know the details of the
patients’ clinical data.
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Renal biopsies were performed according to the clinical
needs of the patients in the Juntendo University Hospital.
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded tissue sections. Briefly, sections (3 μm
thick) were autoclaved at 121°C for 10 minutes in a 0.01 M
citrate buffer (pH 6.0). To block endogenous biotin, the
slides were treated with an avidin/biotin blocking kit
(Vector Laboratories, Burlingame, CA) and treated with
0.3% H2O2 in methanol to inhibit endogenous peroxidase
activity. The sections were visualized with first antibody for
polyclonal goat anti-human TWEAK antibody (pAb)
(R&D Systems), rabbit anti-human Fn14 pAb (Bio-
world Technology, St. Louis Park, MN), or isotype-
matched control IgG, and biotin-conjugated rabbit
anti-goat IgG (DAKO, Carpinteria, CA) or goat anti-
rabbit IgG (DAKO) by using avidin/biotin-peroxidase
method.
Cell culture
Conditionally immortalized mouse podocytes were kindly
provided by Dr. K. Asanuma (Kyoto University, Kyoto,
Japan) and Dr. P. Mundel (Massachusetts General Hos-
pital, Boston, USA) and were cultured as previously de-
scribed [29,30]. Podocytes were maintained in an RPMI
1640 medium (Sigma, Tokyo, Japan) supplemented with
10% FBS, penicillin/streptomycin (Life Technologies, CA),
and 10 U/ml interferon-γ at 33°C. Podocytes were incu-
bated at 37°C for 10–14 days to differentiate without
interferon-γ.
Mouse mesangial cells (MMC, SV 40 MES-13) were
obtained from the American Type Culture Collection
(Manassas, Va). The cells were grown at 37°C in a 3:1
mixture of Dulbecco’s Modified Eagle’s and Ham’s F12
media (Sigma) supplemented with 5% FBS, and penicil-
lin/streptomycin.
Cell proliferation assay
MMC (5 × 103 cells per well) were seeded in 96-well
plates in duplicate with medium containing 0.1% FBS.
Recombinant mouse TWEAK (R&D Systems) at 0–
1000 ng/ml was added at the beginning of the experiment.
After stimulation of MMC with TWEAK for 24 hours, cell
proliferation ELISA using BrdU was performed with a col-
orimetric immunoassay kit (Roche Diagnostics, Mannheim,
Germany) following the manufacturer’s instructions.
Cytokine detection
The concentration of MCP-1 in supernatants of MMC
culture was examined by a mouse MCP-1 ELISA kit
(R&D Systems) according to the manufacturer’s instruc-
tions. Recombinant mouse TWEAK was used at 0, 10,
and 100 ng/ml, for 3, 6, 12, and 24 hours.Wound healing assay
Wound healing assays were conducted as reported
previously [30,31]. Differentiated wild-type podocytes
(5 × 105) were seeded overnight in six-well plates.
Monolayers were scratched with a 200 μl pipette tip,
washed with PBS and added to fresh medium with
TWEAK (0–1000 ng/ml). The monolayers were photo-
graphed using a grid as a marker, and the wound width
(μm) was measured at 0, 12 and 24 hours using BZ-II
Measurement Module (Keyence, Osaka, Japan) with BZ
Viewer™ (Keyence). Migratory rates were calculated as
(A − B)/A × 100% or (A − C)/A × 100%, with A,B, and C
reflecting the width of the wound at 0, 12, or 24 hours,
respectively.
Statistical analyses
Data were expressed as proportions, mean ± SD, or
median (interquartile range [IQR]) as appropriate.
Categorical variables were compared using the χ2 test.
Continuous variables were compared using unpaired t
test or Mann–Whitney U test as appropriate. We eval-
uated the differences in each biochemical parameter
among the glomerular diseases by a one-way analysis
of variance (ANOVA) followed by a multiple compari-
son analyses. Each multiple comparison analysis was
performed with Tukey’s HSD (honest significance
difference) mean separation test (parametric) or a
Steel-Dwass test (nonparametric). Correlate variables
were evaluated using Spearman’s rank correlation co-
efficient test. Statistical analyses were performed using
JMP 9.0 statistical software (SAS Institute, Cary, NC)
and GraphPad Prism version 6.0 software (GraphPad
Software, San Diego, CA). A P value <0.05 was consid-
ered significant.
Results
Demographic and clinical characteristics of patients with
IgAN and controls
The demographic and clinical characteristics of the
IgAN patients and controls are summarized in Table 1.
The mean age of the IgAN patients at diagnosis was
34.0 ± 10.9 years (range, 15–65 years). The MCD pa-
tients, the MN patients, and the LN patients excreted
significantly more urinary protein than IgAN patients.
The levels of uTWEAK in the IgAN patients (median:
94.3, IQR 65.1–147.1 pg/mgCr) did not differ from any
other disease groups. In our cohort, however, the levels
of uTWEAK in the patients with IgAN, LN, MN, FSGS,
and MCD were significantly higher than in the healthy
controls (P < 0.001, P = 0.001, P < 0.001, P = 0.005, and
P = 0.001, respectively).
The levels of uTWEAK were significantly correlated
with urinary protein levels in IgAN patients (r = 0.54,
P < 0.001, Figure 1A), in MN patients (r = 0.77, P = 0.003),
Table 1 Demographic and clinical characteristics of IgAN patients, disease controls, and healthy controls




(n = 116) (n = 18) (n = 12) (n = 8) (n = 12) (n = 50)
Age (years) 34.0 ± 10.9 33.0 ± 9.9 55.7 ± 9.5 A-E 35.9 ± 13.1 31.8 ± 19.3 33.6 ± 5.5 <0.001
Men, n (%) 53 (45.7) 2 (11.1) 9 (75.0) 5 (62.5) 6 (50.0) 32 (64.0) 0.002
BMI (kg/m2) 21.7 ± 3.0 21.7 ± 4.5 23.5 ± 2.5 24.3 ± 5.3 23.3 ± 3.8 22.0 ± 2.0 0.08
Mean arterial pressure
(mmHg)
83.8 ± 13.8 82.4 ± 16.3 87.3 ± 8.9 85.8 ± 10.1 79.1 ± 8.1 86.0 ± 11.0 0.62
eGFR (ml/min per
1.73 m2)
81.9 ± 29.0 82.8 ± 32.6 79.3 ± 29.4 76.8 ± 28.3 95.7 ± 23.7 N/A 0.56
CKD Stages 1/2/3/4/5
(KDOQI) (%)a
32/47/20/1/0 44/39/11/0/6 25/50/25/0/0 38/50/0/13/0 50/42/8/0/0 - 0.13
Urinary protein
excretion (g/gCr)
0.61 ± 0.88 2.22 ± 2.62 F 3.76 ± 2.97 G 1.70 ± 1.91 5.46 ± 4.35 H,I,J N/A <0.001
uTWEAK (pg/mgCr,
median, IQR)
94.3 (65.1, 147.1)K 130.8 (70.2, 163.8)L 151.9 (98.8, 285.1)M 168.9 (107.8, 304.7)N 180.6 (92.8, 331.8)O 64.2 (32.2, 84.9) <0.001
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; uTWEAK, urinary TWEAK; IQR, interquartile range; IgAN, IgA nephropathy; LN,
lupus nephritis; MN, membranous nephropathy; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; NA, not available; ANOVA, analysis of
variance; HSD, honest significant difference.
aCKD stage 1, 2, 3, 4, and 5 were divided by eGFR ≥90, 60–89, 30–59, 15–29, and <15, respectively.
Data are expressed as proportions, mean ± SD, or median (interquartile range [IQR]) as appropriate. Differences among the groups were analyzed by a one-way ANOVA. The
multiple comparisons for age, BMI, mean arterial pressure, eGFR, and urinary protein excretion were performed by Tukey’s HSD mean separation tests. A nonparametric Steel-
Dwass test was used for uTWEAK. Differences between the disease groups in gender and CKD stages were determined by χ2 tests. A: P< 0.001 vs. IgAN; B: P< 0.001 vs. LN;
C: P< 0.001 vs. FSGS; D: P< 0.001 vs. MCD; E: P< 0.001 vs. healthy controls; F: P= 0.001 vs. IgAN; G: P< 0.001 vs. IgAN; H: P< 0.001 vs. IgAN; I: P< 0.001 vs. LN; J: P< 0.001 vs.
FSGS; K: P< 0.001 vs. healthy controls; L: P= 0.001 vs. healthy controls; M: P< 0.001 vs. healthy controls; N: P= 0.005 vs. healthy controls; O: P= 0.001 vs. healthy controls.
Figure 1 Relationship between the levels of uTWEAK and clinical and histopathologic characteristics in patients with IgAN. The levels
uTWEAK at the time of renal biopsy in 116 IgAN patients showed significantly correlations with: (A) urinary protein excretion, r = 0.54, P < 0.001;
and (B) extracapillary proliferation, r= 0.32, P< 0.001. (C) There was no significant association between the levels of serum TWEAK (sTWEAK) and uTWEAK
(r = 0.05, P= 0.65). (D) Box plots of the levels of uTWEAK with different histological grades in patients with IgAN. The level of uTWEAK in Grade III + IV
(n= 12, median: 145.7, IQR 97.5-195.6 pg/mgCr) was significantly higher than those in Grade I (n= 63, median: 78.6, IQR 52.3-115.7 pg/mgCr; **P< 0.001) or
Grade II (n= 41, median: 103.7, IQR 70.9–162.5 pg/mgCr; *P< 0.05). The lines in the box plots and the error bars are median and 10–90 percentiles.
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was detected between the levels of uTWEAK and urinary
protein excretion in LN patients (r = 0.17, P = 0.51) and
FSGS patients (r = 0.20, P = 0.65). There was a significant
correlation between the levels of uTWEAK and the extraca-
pillary proliferation in IgAN patients (Figure 1B).
Clinical and histopathologic characteristics in subgroups
of IgAN patients
The IgAN patients were next divided into three equal
groups according to the tertiles of the uTWEAK distri-
bution: Group 1, uTWEAK levels <72.3 pg/mgCr; Group
2, uTWEAK levels between 72.3 and 123.0 pg/mgCr;
and Group 3, uTWEAK levels >123.0 pg/mgCr (Table 2).Table 2 Clinical and histopathologic characteristics in subgro




Age (years) 33.2 ± 10.2
Men, n (%) 16 (41.0)
BMI (kg/m2) 21.4 ± 2.7
Mean arterial pressure (mmHg) 82.8 ± 11.2
eGFR (ml/min per 1.73 m2) 83.3 ± 25.8
CKD Stages 1, 2, 3, and 4 (KDOQI) (%)
Stage 1: >90 15 (38.5)
Stage 2: 60-89 16 (41.0)
Stage 3: 30-59 7 (17.9)
Stage 4: 15-29 1 (2.6)
Urinary protein excretion (g/gCr) 0.28 ± 0.30
class 0: <0.30 24 (61.5)
class 1: 0.30-0.99 13 (33.3)
class 2: 1.00-2.99 2 (5.2)
class 3: ≥3.00 0 (0)
sTWEAK (pg/ml, median, IQR) 921.4 (828.8, 1089.1)
Histopathologic mean ± SD (range)
Total glomerular number 18.2 ± 7.9 (8–42)
Global glomerular sclerosis (%) 7.6 ± 11.0 (0–50.0)
Mesangial hypercellularity score 0.47 ± 0.29 (0.09-1.3)
Endocapillary hypercellularity (%) 3.0 ± 5.8 (0–26.7)
Segmental glomerulosclerosis (%) 4.0 ± 8.1 (0–40.0)
Interstitial fibrosis (%) 14.3 ± 5.7 (6.3-28.0)
Extracapillary proliferation (%) 3.6 ± 6.6 (0–25.0)
Histological-grade I/II/III/IV (%)a 69/28/0/3
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; uTW
analysis of variance; HSD, honest significant difference.
aHistological-grade was classified according to the histological classification for IgAN
Differences among the groups were analyzed by a one-way ANOVA. The multiple c
proliferation were performed by Tukey’s HSD mean separation tests. Categorical da
C: P = 0.009 vs. Group 1; D: P = 0.02 vs. Group 1.The urinary protein excretion, degree of interstitial fibrosis
and extracapillary proliferation in the IgAN patients of
Group 3 were significantly higher than the IgAN patients of
Group 1 (P < 0.001, P = 0.009, and P = 0.02, respectively).
Among the cases, we observed no significant association
between the levels of serum TWEAK (sTWEAK) and
the clinical and histological parameters, including
uTWEAK (Figure 1C).
Association of uTWEAK levels with histologic
characteristics
The distribution by histological Grades I, II, III, and IV
was 54.3, 35.3, 7.8, and 2.6%, respectively. The level of
uTWEAK in Grade III + IV was significantly higher thanups of IgAN patients defined by tertiles of uTWEAK
IgAN Group 2 (n = 39) IgAN Group 3 (n = 38) P
valuepg/mgCr, median (IQR) pg/mgCr, median (IQR)
96.4 (81.2, 105.7) 163.8 (147.1, 190.6)
32.9 ± 10.9 36.1 ± 11.6 0.39
25 (64) 12 (32) 0.01
22.4 ± 2.9 21.4 ± 3.3 0.22
84.1 ± 19.2 84.6 ± 9.5 0.84
82.4 ± 35.2 80.0 ± 25.8 0.88
9 (23.7) 13 (34.2) 0.35
23 (60.5) 15 (39.5)
6 (15.8) 10 (26.3)
0 (0) 0 (0)
0.51 ± 0.60 1.03 ± 1.28 A,B <0.001
20 (51.3) 11 (28.9) 0.004
8 (20.5) 13 (34.2)
11 (28.2) 11 (28.9)
0 (0) 3 (7.9)
957.1 (874.3, 1103.7) 941.5 (836.4, 1124.6) 0.95
19.6 ± 7.5 (8–37) 18.7 ± 8.0 (8–44) 0.74
11.0 ± 13.5 (0–62.5) 13.7 ± 13.3 (0–44.4) 0.11
0.57 ± 0.30 (0.1-1.6) 0.61 ± 0.25 (0.13-1.1) 0.12
1.6 ± 2.9 (0–13.3) 3.7 ± 5.6 (0–20.0) 0.15
5.5 ± 7.4 (0–37.5) 6.6 ± 9.1 (0–33.3) 0.37
15.4 ± 5.6 (3.8-32.8) 18.6 ± 7.1 (7.9-39.7) C 0.01
5.9 ± 7.5 (0–29.4) 8.5 ± 8.9 (0–37.5) D 0.02
59/33/8/0 34/44/16/5 0.03
EAK, urinary TWEAK; sTWEAK: serum TWEAK; IQR, interquartile range; ANOVA,
in Japan [28].
omparisons for urinary protein excretion, interstitial fibrosis, and extracapillary
ta were determined by χ2 tests. A: P < 0.001 vs. Group 1; B: P = 0.02 vs. Group 2;
Table 4 Univariate and multivariate regression analyses






r P value t P value
Global glomerular sclerosis (%) 0.20 0.03 1.28 0.20
Mesangial hypercellularity score 0.14 0.13 0.27 0.79
Endocapillary hypercellularity (%) 0.18 0.05 1.49 0.14
Segmental glomerulosclerosis (%) 0.11 0.23 0.45 0.65
Interstitial fibrosis (%) 0.24 0.01 1.30 0.20
Extracapillary proliferation (%) 0.32 <0.001 2.72 0.007
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fication, the levels of uTWEAK in IgAN patients with
M1, En1, S1, and T1, 2 were relatively higher than those
with M0, En0, S0, and T0, although a significant differ-
ence was not detected (Table 3).
Both univariate and multivariate logistic analyses were
performed to evaluate the impact of uTWEAK on the
histologic lesions (Table 4). Interstitial fibrosis and extra-
capillary proliferation were statistically significant factors
that were associated with the levels of uTWEAK. In a
multivariate analysis, extracapillary proliferation was a
significant independent factor that impacted the levels of
uTWEAK.
The changes in the levels of uTWEAK at renal biopsy and
during follow-up
During follow-up with a median duration of 36 (IQR
24–40) weeks, we obtained urine samples from 37 pa-
tients with therapeutic responses. There were 12 patients
achieving CR, 25 patients achieving PR, meaning that all
patients responded to the treatment. At diagnosis the
levels of uTWEAK in the patients with CR were signifi-
cantly higher than those in PR (P < 0.05). In a compari-
son of the levels of uTWEAK at diagnosis with that of
follow-up, the levels of uTWEAK in patients with CR
and PR decreased significantly (Figure 2, A and B).
Expression of TWEAK and Fn14 in renal biopsies from
IgAN patients
We investigated the localization of TWEAK in the renal bi-
opsies from IgAN patients by immunohistochemistry. The
expression of both TWEAK and Fn14 were increased in
renal tubular cells in IgAN patients (Figure 3, A, B, D, and
E). In the IgAN patients with glomerular crescents,
TWEAK and Fn14 were detected in glomerular tufts and




IgAN patients, uTWEAK P
valuean (%) (pg/mgCr, median, IQR)
M 0 59 (50.9) 92.1 (64.5, 136.7) 0.49
1 57 (49.1) 96.4 (66.6, 154.8)
E 0 77 (66.4) 87.3 (64.7, 141.1) 0.18
1 39 (33.6) 106.0 (67.8, 160.1)
S 0 62 (53.4) 81.2 (59.9, 145.5) 0.20
1 54 (46.6) 103.5 (73.3, 151.2)
T 0 106 (91.4) 91.1 (64.9, 145.5) 0.21
1, 2 10 (8.6) 150.9 (63.9, 184.7)
Abbreviations: uTWEAK, urinary TWEAK Mesangial hypercellularity score
of ≤0.5 (M0) or >0.5 (M1), absence (E0) or presence (E1) of endocapillary
hypercellularity, absence (S0) or presence (S1) of segmental glomerulosclerosis, and
tubular atrophy/interstitial fibrosis of 0–25% (T0), 26–50% (T1), and >50% (T2).
aMann-Whitney U test.with MCD), two images of the same glomeruli showed very
slight staining for TWEAK and Fn14 in glomeruli, while in-
tense staining was observed in renal tubular cells (Figure 3,
C and F). TWEAK and Fn14 were also detected in the
glomeruli of other crescentic glomerulonephritis (GN), in-
cluding ANCA-associated renal vasculitis (data not shown).
TWEAK regulates mesangial cell proliferation and
podocyte migration
To confirm whether TWEAK may affect the prolifera-
tion or apoptosis of kidney cells, we performed a cell
proliferation assay. The proliferation of MMC was sig-
nificantly increased under the stimulation of TWEAK
(10–1000 ng/ml), with the highest effect at 1000 ng/ml
(Figure 4A). We examined TWEAK-induced MCP-1 ex-
pression in MMC. Protein expression was increased in
both the dose of TWEAK and time-dependent manners
(Figure 4B).
Next, we analyzed whether TWEAK has a role in the
motility of podocytes. In the wound healing assay, as
compared with the control at 24 hours, TWEAK (100,
1000 ng/ml) significantly enhanced cell motility in differ-
entiated podocytes (Figure 4C).
Discussion
In the present study, we showed that the urine excretion
of soluble TWEAK is associated with clinicopathological
findings in patients with IgAN. Notably, we also demon-
strated that TWEAK significantly enhanced cell motility
in podocytes and in the proliferation of mesangial cells,
known to be an important feature of the histopathology
of IgAN. Mesangial cells and podocytes constitutively
express TWEAK and Fn14 [18,23]. Most cases of pro-
teinuria are associated with the effacement of podocyte
foot processes, which represents podocyte dynamics
in vivo or the motility of podocytes [13,30]. Podocytes
stay attached to the GBM, but an altered cell motility of
podocytes results in foot processes effacement and
proteinuria. Since TWEAK enhanced podocyte motility,
Figure 2 The changes in the levels of uTWEAK in patients with IgAN during follow-up. (A) Patients with clinical remission (n = 12): the
levels of uTWEAK at the time of biopsy (median: 149.2, IQR 113.8–181.8 pg/mgCr) decreased significantly compared with those of therapy-induced
clinical remission (median: 53.8, IQR 33.6–88.5 pg/mgCr; P = 0.003). (B) Patients with partial remission (n = 25): the levels of uTWEAK at the time of
biopsy (median: 87.3, IQR 67.1–134.3 pg/mgCr) also decreased compared with those of therapy-induced partial remission (median: 58.4,
IQR 42.6-81.3 pg/mgCr; P = 0.009). Wilcoxon signed-rank test.
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velopment of proteinuria. In fact, we confirmed that the
levels of uTWEAK were significantly correlated with
urinary protein excretion not only in IgAN patients, but
also in MCD and MN patients. However, no correlation
was observed between the levels of uTWEAK and the
degree of proteinuria in LN patients, as seen in a previ-
ous study [8]. Therefore, LN with proteinuria may be
affected by additional other factors or mediators.A B










Figure 3 Expression of TWEAK and Fn14 in renal biopsies from IgAN
and Fn14 (D, E) were detected in glomerular crescents (the areas delineate
minimal change disease (C, F)], there was very slight staining for TWEAK an
tubular cells. Scale bar = 50 μm.The underlying mechanisms as to why TWEAK relates
to the development of proteinuria are unknown. How-
ever, experimental studies, using pharmacological or
genetic approaches, have clearly shown that TWEAK
activates Fn14 following renal inflammation [22,32].
TWEAK activates the canonical nuclear factor-kB (NF-
κB) pathway to induce the expression of both soluble
and membrane-bound inflammatory chemokines, in-
cluding MCP-1, RANTES and CXCL16 [18,20,23]. TheC
rescent - (ii) Minimal change disease
F
patients was examine. Immunohistochemistry for both TWEAK (A, B)
d by the squares). In the controls [renal biopsies from patients with





















Figure 4 TWEAK actions on renal cells in vitro. (A) TWEAK modulates mesangial cells proliferation. The proliferation of MMC is significantly
increased following stimulation with TWEAK (10–1000 ng/ml) for a 24-hour incubation. Data are expressed as mean ± SD of five independent experiments.
**P< 0.001 vs. control; *P< 0.05 vs. control. (B) MCP-1 secretion in response to TWEAK stimulation is dose and time dependent. MCP-1 protein levels in
TWEAK stimulated MMC supernatants are shown. Data are expressed as mean ± SD of three independent experiments. *P< 0.05, TWEAK at 10, 100 ng/ml
vs. control. (C) TWEAK stimulates podocyte motility as evaluated by wound healing assay. After the scraping of the podocyte cell layer, cells have started
to migrate into the wound track. The wound closures were significantly enhanced in the presence of TWEAK (100, 1000 ng/ml) at 24 hours. Compared
with the control, TWEAK enhanced directed cell migration in differentiated podocytes. Data are expressed as mean ± SD of five independent experiments.
*P< 0.05, TWEAK at 100, 1000 ng/ml vs. control 24 hours. Scale bar = 200 μm.
Sasaki et al. BMC Nephrology  (2015) 16:27 Page 8 of 10present results showed that TWEAK modulates cell
proliferation and MCP-1 production in glomerular
mesangial cells in a dose-dependent manner. Recently, it
has been demonstrated that TWEAK activates NF-κB
and increases MCP-1 expression in podocytes [33].
Podocyte-derived MCP-1 could activate the cysteine-
cysteine chemokine receptor 2 (CCR2) in podocytes in a
autocrine or paracrine manner. Furthermore, in podo-
cytes MCP-1 has been reported to promote motility
[34,35], actin cytoskeleton rearrangement [35], and de-
creased nephrin expression [36]. Accordingly, these datamay indirectly support our findings and suggest that the
TWEAK/Fn14 pathway increases inflammatory settings
and thus further enhances cell motility in podocytes
leading to proteinuria.
The Oxford classification of IgAN identified patho-
logical variables, the MEST score was associated closely
with kidney failure, which was also validated in previous
studies [37-40]. A recent study from Japan reported that
a histological classification of IgAN could identify the
risk of progression to ESRD [28]. Multivariate logistic
analysis showed that the risk of progression to ESRD
Sasaki et al. BMC Nephrology  (2015) 16:27 Page 9 of 10was higher in histological Grades II, III, and IV than in
histological Grade I. Our results confirmed that the
levels of uTWEAK increased in parallel with the
Japanese histological grade. However, we did not detect
any significant relationship between uTWEAK and each
parameter in the Oxford classification. Extremely mild
and severe cases were excluded in this classification [41].
It is possible that our study cohort consisted of popu-
lations that were lower in proteinuria and higher in
eGFR as compared with that of other studies [37-39]
as we could not detect differences in each histologic
parameter.
In a multivariate analysis, we found that extracapillary
proliferation was a significant independent factor that
was associated with the levels of uTWEAK. To confirm
whether these findings are relevant to pathophysiological
conditions, we evaluated both TWEAK and Fn14 expres-
sion in renal biopsies. In the control kidneys, we ob-
served a very slight staining for TWEAK and Fn14 in
glomeruli. By contrast, TWEAK and Fn14 were detected
in glomerular crescents in the IgAN patients with
crescents, which is consistent with the clinical relation-
ship between uTWEAK and extracapillary proliferation.
Although glomerular crescents are recognized as a het-
erogeneous composition of cells and matrix, recent
evidence suggests the presence of podocytes in these
structures [42-44]. The dedifferentiation of podocytes
leads to podocyte proliferation within Bowman’s space
and the collapse of glomerular tufts [13]. Further prolif-
eration of podocytes and parietal cells result in the for-
mation of crescents [13,45]. Moreover, the potential
contribution of proinflammatory cytokines and macro-
phages during the effector phase of crescentic GN has
been indicated [46]. These findings, together with
TWEAK-induced cell motility in podocytes and TWEAK
and Fn14 expression in crescents of IgAN suggest that
TWEAK/Fn14 may be involved in the podocyte alter-
ations and subsequent crescent formation.
The present study showed that the levels of uTWEAK
in IgAN patients significantly decreased according to the
treatment responses. Urinary biomarkers are attractive
candidates for accurately reflecting the activity of kidney
injury. Our findings indicate that uTWEAK may be use-
ful as a biomarker to predict the histologic findings, es-
pecially crescent formation and disease activity in IgAN.
Although we could not identify which cells are respon-
sible for the TWEAK production, our results indicate
that TWEAK locally production and the subsequent in-
flammatory responses may be involved in podocytes,
mesangial cells, and infiltration of macrophages in the
kidney. It appears that there are different causes of in-
creased uTWEAK levels between the IgAN patients and
the MCD patients. In the MCD patients, podocyte injur-
ies and loss of GBM charge would result in the massiveleakages of TWEAK, and probably be the main cause of
the high levels of uTWEAK. On the other hand, the pro-
duction of TWEAK in the IgAN patients may be associ-
ated with the leakages and injured glomerular cells such
as podocytes and mesangial cells.
This study has several limitations. First, the levels of
uTWEAK do not clearly distinguish the patient groups,
there seems to be substantial overlap between IgAN and
CKD. Second, a decrease in uTWEAK is shown in IgAN
patients who receive steroid therapy, we were not able
to analyze the changes of uTWEAK in those patients
who did not receive immunosuppressive therapies be-
cause urine samples were not obtained. Finally, this
study was performed only in Juntendo University Hos-
pital, and the number of patients was small. Further
studies are required to elucidate the mechanisms under-
lying TWEAK/Fn14 signaling and its role in pathophysi-
ology of patients with IgAN.Conclusion
In conclusion, the relationship between the levels of
uTWEAK and clinicopathological findings observed in
this study suggests that TWEAK/Fn14 system affects
crescent formation and proteinuria in patients with
IgAN.
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